The amphetamine-based drug, prescribed to U.S.
students to control ADHD, did not perform sufficiently better than a
placebo as an add-on therapy for adults who had inadequately
responded to two common types of anti-depressants, the company said.
London-listed Shire said based on the results of the two clinical
trials, it would no longer pursue the clinical development program
for major depressive disorders.
"While this news in major depressive disorder is disappointing for
patients and Shire, we will later in the year be filing with the FDA
for a new indication for Vyvanse in Binge Eating Disorder in adults,
and Vyvanse is an effective and leading treatment for ADHD," Shire
Chief Executive Officer Flemming Ornskov said in a statement.
The company had said in November that the drug was predicted to
achieve sales of $1.2 billion this year for ADHD.
(Reporting by Richa Naidu in Bangalore
and Paul Sandle in London; Editing by Lisa Shumaker)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.